Impact BioMedical Inc.
The research page contains a warning that has not been mapped to a supported model interpretation. The company research remains available, but the complete score is withheld until the warning is reviewed.
IBO · Price history
Price at last available close
$3.55
−$2.06 (-36.72%) 1M
2026-10-27
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About Impact BioMedical Inc.
Primary reporting period: 2025-12-31 · Research updated Oct 13, 2026. A research update is not a new financial filing.
Who they are
Houston, Texas-based Impact BioMedical Inc., founded in 2018, focuses on discovering and developing innovative products and therapeutic options for both specialty biopharmaceuticals and consumer healthcare markets. The company features several key technologies: its "Linebacker" platform utilizes small molecule electrophilically enhanced polyphenol compounds with potential applications in treating cancer, inflammatory diseases, and neurological conditions. Additionally, "Laetose" technology, a unique blend of sugar and inositol, is designed to counteract the inflammatory and metabolic responses usually triggered by sugar consumption.
How they make money
Impact BioMedical Inc. operates by discovering, confirming, and patenting unique science and technologies. It generates revenue through licensing, co-development, joint ventures, and other collaborative relationships with external partners in the healthcare and wellness sectors, while also exploring potential direct sales for commercialization.
Products & services
The company focuses on the development of intellectual property and technologies in human healthcare and wellness, including assets such as Laetose, which has a unique composition patent.
Brands & revenue mix
A proprietary technology with a unique composition patent allowed in the United States.
Separate brand revenue is not available in this research.Source
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Product / operating segments
No reconciled product or operating-segment revenue breakdown is available for the current research period. Company-wide revenue remains separate from segment disclosure.
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer types
Customer categories were not separately identified in the reviewed source set.
Customer concentration
No quantified customer-concentration disclosure is available in the current saved research.
Suppliers, materials & equipment
No supplier relationships were confirmed in the sources reviewed. This does not mean the company has no suppliers.
Strengths
- Portfolio of patented science and technologies in healthcare and wellnessSource
Risks
- Going concern audit opinion regarding the company's ability to continue as a going concernSource
Company-specific research
Questions worth answering for IBO
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •Can IBO maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
- •How long can IBO fund negative free cash flow using its current cash position before it may need more debt or new shares?
- •How is IBO likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
- •What future growth or profitability would be needed to justify IBO's current valuation?
- •What does the current fundamental change risk warning mean for the reliability or interpretation of IBO's score?
Essential Investment Snapshot
Market Cap
$30.3M
P/E Ratio
-4.5
EPS
$-1.23
52-Week High
$10.51
52-Week Low
$4.67
Beta
2.76
Shares Outstanding
8.5M
Total Debt
$0
Dividend
No current dividend
Liquidation Value / Share
$1.64
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Strong downward momentum
Extreme movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for IBO
Detected from reported data — verify before acting.Debt service risk
Interest coverage is low (~-5.4x). Earnings may be strained to cover interest expense.
M&A headline · Sep 16, 2026
Impact Biomedical Inc Announces Filing of Form F-4 Registration Statement in Connection with Proposed Merger with Zoar Ltd. (f/k/a Dr. Ashley's Limited) — This is a provider-linked headline, not an independently confirmed event. Check the article and company filings for the subject, proposed/completed status, and subsequent updates.
GlobeNewsWireReverse-split headline · Sep 14, 2026
CORRECTED — Impact Biomedical Inc (NYSE: IBO) Announces 1 for 12.62 Reverse Stock Split to Pursue Completion of Merger with Zoar Limited (f/k/a Dr Ashleys Limited) — This is a provider-linked headline, not an independently confirmed event. Check the article and company filings for the subject, proposed/completed status, and subsequent updates.
GlobeNewsWireReverse-split headline · Sep 11, 2026
Impact BioMedical Inc (NYSE American: IBO) Announces 1 for 12.62 Reverse Stock Split to Pursue Completion of Merger with Zoar Ltd. (previously Dr. Ashley's Ltd. — This is a provider-linked headline, not an independently confirmed event. Check the article and company filings for the subject, proposed/completed status, and subsequent updates.
GlobeNewsWireCommunity Sentiment
0 active · 0 total callsNo personal call yet on IBO.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Portfolio of patented science and technologies in healthcare and wellness.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Biotechnology industry.
- −Going concern audit opinion regarding the company's ability to continue as a going concern.
- −Diluted weighted-average shares increased 784.8% year over year.
- −Negative free cash flow may increase the need for outside financing and dilution.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
Score changes will appear once more historical records are available.
Price vs. Value
Valuation unavailableCurrent Price
$3.55
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | $35K | $32K | $0.00 | $0.00 | ···· | ···· | ···· |
| Cost of Revenue | $424K | $424K | $0.00 | $0.00 | ···· | ···· | ···· |
| Gross Profit | -$389K | -$392K | $0.00 | $0.00 | ···· | ···· | ···· |
| Research & Development | $284K | $340K | $278K | $1.7M | ···· | ···· | ···· |
| SG&A Expenses | $3.0M | $2.0M | $1.8M | $1.1M | ···· | ···· | ···· |
| Operating Expenses | $4.7M | $3.9M | $28.8M | $4.0M | ···· | ···· | ···· |
| EBITDA | -$401K | -$12.5M | -$22.6M | -$2.8M | ···· | ···· | ···· |
| Operating Income | -$5.1M | -$4.3M | -$28.8M | -$4.0M | ···· | ···· | ···· |
| Interest Expense | $262K | $793K | $117K | $444K | ···· | ···· | ···· |
| Income Before Tax | -$1.8M | -$14.4M | -$24.7M | -$4.4M | ···· | ···· | ···· |
| Income Tax Expense | -$2.6M | -$2.6M | $33K | $0.00 | ···· | ···· | ···· |
| Net Income | $789K | -$11.8M | -$24.7M | -$4.3M | ···· | ···· | ···· |
| Basic EPS | $-1.23 | $-4.80 | $-0.09 | $-0.88 | ···· | ···· | ···· |
| Basic Shares | 8.54M | 2.50M | 3.31M | 4.77M | ···· | ···· | ···· |
| Diluted Shares | 8.54M | 2.50M | 3.31M | 4.77M | ···· | ···· | ···· |
Earnings Summary
Revenue
$3000
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$0.08
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
-100.0%
Cash Change
-98.4%
Margin Change
+181642.9 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Margins expanded
- Debt reduced
What Weakened
- Cash position declined
Potential Score Impact
Positive indicators included debt levels, net income margin. Pressure indicators included revenue growth, EPS growth, cash levels. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue declined 57.1%. EPS declined 99.4%. Cash declined 98.4%. Total debt declined 100.0%. Net income margin improved by 181642.9 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
2 historical records2 historical score records available.
Historical Score Chart
2 of 2 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
BiotechnologyNews
Impact Biomedical Inc Announces Filing of Form F-4 Registration Statement in Connection with Proposed Merger with Zoar Ltd. (f/k/a Dr. Ashley's Limited)
CORRECTED — Impact Biomedical Inc (NYSE: IBO) Announces 1 for 12.62 Reverse Stock Split to Pursue Completion of Merger with Zoar Limited (f/k/a Dr Ashleys Limited)
Impact BioMedical Inc (NYSE American: IBO) Announces 1 for 12.62 Reverse Stock Split to Pursue Completion of Merger with Zoar Ltd. (previously Dr. Ashley's Ltd.
Rumor Mill · IBO
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial